FOMXinactive

FOAMIX PHARMACEUTICALS LTD.

Healthcare·Dermatology·Commercial
Dermatology

FOAMIX PHARMACEUTICALS LTD. (FOMX): 7 pipeline candidates. Updated within the last hour.

8.3/10

BioSniper Score

3-factor signal · derived from public data

Cash RunwayN/A

N/A

Financial Health5.0

D/E 3.62 · 0% dilution

Pipeline Maturity10.0

Lead: Approved

Pipeline Breadth10.0

7 candidates

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

A transparent, data-derived signal for FOAMIX PHARMACEUTICALS LTD.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.

Key Financials

Market Cap

—

Cash

$44.6M

Quarterly Burn

—

Runway

—

Revenue

$135K

Pipeline (7 candidates)

DrugPhase
amzeeqApproved
fcd105Preclinical
finaceaApproved
fmx101BLA Filed
fmx103Phase 3
fmx109Preclinical
fmx110Preclinical

Frequently asked questions

How many drug candidates are in FOAMIX PHARMACEUTICALS LTD.'s pipeline?

FOAMIX PHARMACEUTICALS LTD. (FOMX) has 7 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.

What is FOAMIX PHARMACEUTICALS LTD.'s lead drug candidate?

FOAMIX PHARMACEUTICALS LTD.'s most advanced tracked candidate is amzeeq (Approved) for inflammatory lesions of non-nodular moderate-to-severe acne vulgaris.

Get the full picture on FOAMIX PHARMACEUTICALS LTD.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.

Start Free AnalysisBrowse Calendar